



Group IV: Claims 31-32, 34-41, drawn to a method of modulating immune response, classified in class 424, subclass 193.1;

Group V: Claims 33, 34-42, drawn to method for treating an autoimmune disorder, classified in class 424, subclass 193.1;

Group VI: Claims 43-44, drawn to a method of increasing immunopotency of cancer cell, classified in class 424, subclass 277.1;

Group VII: Claims 45-47, drawn to a recombinant cell, classified in class 435, subclass 93.1;

Group VIII: Claims 48-53; drawn to a kit comprising proteins, classified in claims 530, subclass 350;

Group IX: Claims 48-53; drawn to a kit comprising nucleic acid, classified in claims 514, subclass 44; and

Group X: Claims 54-63; drawn to a method for identifying HSP fragment, classified in class 435; subclass 7.1.

RECEIVED  
TECH CENTER 435  
DEC 12 2001  
1600/200

In response to the Restriction Requirement, Applicant elects to prosecute Group I, Claims 1-23, drawn to a method for identifying a modulator of HSP-alpha-2M receptor mediated process, classified in class 435, subclass 7.1. Claims 24-63, drawn to non-elected subject matter, have been canceled without prejudice to Applicant's right to pursue the subject matter of the canceled claims in other applications.

Therefore, claims 1-23 will be pending in the instant application. Applicant respectfully requests that the present amendment and remarks be made of record in the instant application. An early allowance of the application is earnestly requested.

Respectfully submitted,

Date: November 2, 2001

Adriane M. Antler 32,605  
Adriane M. Antler (Reg. No.)

By: Eileen E. Falvey 46,097  
Eileen E. Falvey (Reg. No.)

**PENNIE & EDMONDS LLP**  
1155 Avenue of the Americas  
New York, N.Y. 10036-2711  
(212) 790-9090

Enclosures